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Background and purpose: To assess the diagnostic accuracy and inter-observer agreement of T2-weighted
(T2W) and diffusion-weighted (DW) magnetic resonance imaging (MRI) for mapping intra-prostatic
tumour lesions (IPLs) for the purpose of focal dose-escalation in prostate cancer radiotherapy.
Materials and methods: Twenty-six men selected for radical treatment with radiotherapy were recruited
prospectively and underwent pre-treatment T2W+DW-MRI and 5 mm spaced transperineal template-
guided mapping prostate biopsies (TTMPB). A ‘traffic-light’ system was used to score both data sets.
Radiologically suspicious lesions measuring 0.5 cm3 were classified as red; suspicious lesions 0.2–
0.5 cm3 or larger lesions equivocal for tumour were classified as amber. The histopathology assessment
combined pathological grade and tumour length on biopsy (red = 4 mm primary Gleason grade 4/5 or
6 mm primary Gleason grade 3). Two radiologists assessed the MRI data and inter-observer agreement
was measured with Cohens’ Kappa co-efficient.
Results: Twenty-five of 26 men had red image-defined IPLs by both readers, 24 had red pathology-
defined lesions. There was a good correlation between lesions 0.5 cm3 classified ‘‘red” on imaging
and ‘‘red” histopathology in biopsies (Reader 1: r = 0.61, p < 0.0001, Reader 2: r = 0.44, p = 0.03).
Diagnostic accuracy for both readers for red image-defined lesions was sensitivity 85–86%, specificity
93–98%, positive predictive value (PPV) 79–92% and negative predictive value (NPV) 96%. Inter-
observer agreement was good (Cohen’s Kappa 0.61).
Conclusions: MRI is accurate for mapping clinically significant prostate cancer; diffusion-restricted
lesions 0.5 cm3 can be confidently identified for radiation dose boosting.
 2019 The Authors. Published by Elsevier B.V. Radiotherapy and Oncology xxx (2019) xxx–xxx This is an
open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).Although dose-escalation to the whole prostate gland improves
biochemical control of prostate cancer, it is at the expense of
increased rectal toxicity [1–7]. The most important site for local
recurrence is the dominant intra-prostatic tumour lesion (DIL)[8–11] suggesting that focal radiation boosts to the DIL may
improve the therapeutic ratio of prostate radiotherapy [12,13].
Therefore, to achieve this improvement, the accuracy of imaging
to detect the DIL needs to be established.
Diffusion-weightedMR is themostwidelyusedmulti-parametric
magnetic resonance imaging (mpMR) parameter for detecting and
staging prostate cancer, because its quantitation is correlated with
Gleason grade [14–20]. Much of the histopathological correlation
between mpMRI and histopathology has used the gold standard of
whole-mount radical prostatectomy specimens (WM-RP), restrict-
ing analysis of imaging to patients suitable for radical prostatec-
tomy. There is little data correlating mpMR with whole-gland
histology in patients treated with radiotherapy, and in particular
to define DIL’s which might be suitable for radiation boosts.
Mathematical modelling suggests transperineal template map-
ping prostate biopsies (TTMPB) with 5 mm spacing detects lesionsr map-
s://doi.
2 Validation of multiparametric MR for focal dose-escalation using IMRT0.125 cc with 95% certainty [21]. Clinical studies have shown the
accuracy to detect a cancer volume of 0.2 cc or greater and 0.5 cc or
greater is in order of 90–95% respectively with 5 mm sampling
[22,23]. Five mm sampling (giving a sampling density of approxi-
mately 1 core per millilitre) have been shown to have a 95% sensi-
tivity and negative predictive value (NPV) for detecting clinically
significant prostate cancer (defined as 0.5 cm3 or Gleason 7),
although this is significantly reduced with 1 cm mapping [24,25].
If clinically significant lesions are defined as 0.5 cm3 then 5 mm
TTMPB detects 96–100% of such lesions [21,22]. A study classifying
tumour burden from TTMPB core biopsy samples found that a sin-
gle core with maximum cancer core length (MCCL) of 6 mm or
greater had sensitivity to detect more than 95% of lesions of
0.5 cm3 (approximating to a 1 cm diameter lesion). A 4 mm MCCL
detected more than 95% of 0.2 cm3 lesions [23]. The present study
was designed to assess the diagnostic accuracy and inter-observer
agreement of T2W+DW-MRI for mapping IPLs, using TTMPB as the
reference-standard, for the purpose of focal dose-escalation in
patients selected for prostate cancer radiotherapy. This is the
key first step in defining DIL for boost therapy as tested in Phase
3 trials such as FLAME (NCT01168479) and PIVOTALBoost
(ISRCTN80146950).Materials and methods
Study design and patient population
This single institution prospective study was a sub-group of the
DELINEATE trial (ISRCTN04483921). Consenting patients were
recruited sequentially. The trial was approved by the local institu-
tional review board and Regional Ethics Committee and performed
in accordance with European Union guidelines for Good Clinical
Practice. Hormone-naïve patients with National Comprehensive
Cancer Network (NCCN) [26] intermediate or high risk localised
prostate cancer were eligible, patients with seminal vesicle
involvement were excluded. All patients had standard staging
investigations prior to recruitment. Eight weeks after the diagnos-
tic trans-rectal ultrasound-guided biopsies, patients underwent an
MRI comprising of T2W and DW-MR followed by a TTMPB
procedure.MR acquisition
MR imaging was performed on a 1.5T whole-body MR scanner
(Avanto, Siemens, Erlangen). Data were acquired using an endorec-
tal receiver coil (ERC) inflated with 60mls of air in combination
with an external phased array body coil. A 20 mg intramuscular
injection of butylscopolamine bromide (Buscopan, Boehringer
Ingelheim) was administered to reduce peristalsis. The MR proto-
col comprised slice-matched, 3-mm, transverse T2W fast spin-
echo and single-shot echo-planar DWI MRI to cover the entire
prostate gland. T2W fast spin-echo images were also acquired in
sagittal and coronal planes. ADC maps were generated from
all b values 0–800 s/mm2 (parameter details in Supplementary
Appendix A).TTMPB procedure
Patients were anaesthetised, given prophylactic antibiotics and
set-up in the lithotomy position. Biopsies were taken at 5 mm
intervals, apical and basal aspects of the prostate were biopsied
separately if prostate length required. Cores were taken by an
experienced urologist, blinded to the MR results, and each core
was marked with ink at the apical end to define polarity [27].
The supra-urethra area was avoided to prevent urethral injury.Please cite this article as: E. J. Alexander, J. R. Murray, V. A. Morgan et al., Valid
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Two uro-radiologists qualitatively and independently read the
T2W+DW-MRI data. Both radiologists were blinded to the clinical
patient data. Tumour was defined as a low signal-intensity focal
lesion on T2W that showed restricted diffusion on DW-MRI. In
the transitional zone, the homogeneity of the lesion and its mass
effect was also considered in order to differentiate it from stromal
nodules. The prostate was analysed in octants and in Barzell zones
[28], which were modified for analysis taking into account the size
of the prostate gland. If the prostate was short in length the anal-
ysis was performed as a single layer making quadrants or 11
Delineate-modified Barzell zones (DMBZ) (Fig. 1B and Supplemen-
tal Appendix B). Each sector was classified with a traffic-light sys-
tem as red, amber, green or white. Red corresponded to tumour
10 mm in diameter (0.5 cm3) on imaging or MCCL 6 mm of
primary Gleason grade 3 or 4 mm primary Gleason grade 4 on
TTMPB. Amber corresponded to tumour between 7–9.9 mm (0.2–
0.49 cm3)/abnormality equivocal for tumour on imaging or MCCL
4–6 mm of primary Gleason grade 3 or 2 mm of primary Glea-
son grade 4. Green corresponded to tumour 6 mm diameter
(0.2 cm3) or low suspicion of tumour on imaging or MCCL
<4 mm of Gleason 6 or <2 mm of Gleason 7. White corresponded
to no tumour on imaging or biopsy (Fig. 1A). Each sector was anal-
ysed using 2 thresholds; true positive if imaging and pathology
sectors were classified as (1) both red or (2) both either red or
amber. Green and white were not considered to be clinically signif-
icant prostate cancer lesions. If less than 1/3 on a sector on biopsy
was affected by tumour it was classified as negative. The DMBZ
analysis was performed with both strict and flexible methods.
The flexible method allowed for minor geographical mismatch
between sectors; if an imaged sector was positive where corre-
sponding pathology sector was negative, any directly adjacent pos-
itive pathology zones were classified as a true positive [29]. The DIL
was defined as the largest lesion identified by both readers. The
second IPL was defined as the next largest lesion identified by
one or both readers. The pathological DIL and other IPLs were
defined considering the total cancer core length contained in clus-
tered positive biopsies i.e. all adjacent/contiguous biopsies (Fig. 2).Statistical analysis
Statistical analysis was performed in Excel (Microsoft) and Soft-
ware Package for Social Sciences (SPSS v21.0, IBM Corp, NY, USA)
following a pre-specified Statistical Analysis Plan (Supplemental
Appendix B). Descriptive statistics were used to assess tumour vol-
umes and diameters. Sensitivity, specificity, positive predictive
value (PPV) and negative predictive value (NPV) by sector with
binomial 95% confidence intervals (CI) were calculated with Wald
adjustments. All sectors were combined to give diagnostic accu-
racy measurements for each reader. ROC curves compared the
AUC for each reader for significant cancer detection. Inter-
observer agreement was measured with Cohen’s Kappa coefficient
[30] and interpreted as: 0–0.2 slight agreement, 0.21–0.4 fair
agreement, 0.41–0.6 moderate agreement, 0.61–0.8 good agree-
ment, 0.81 almost perfect agreement. Spearman rank correlation
assessed relationships between imaging tumour volumes and
pathological findings. The pre-specified primary end-point was
the diagnostic performance using DMBZ with the red only, flexible
methodology, other endpoints were regarded as exploratory.Results
Twenty-six eligible and consenting patients were recruited
between October 2010 and November 2013 (56 patients were
recruited to the whole study’s initial phase). Patient characteristicsation of T2- and diffusion-weighted magnetic resonance imaging for map-
-modulated radiotherapy (IMRT), Radiotherapy and Oncology, https://doi.
Fig. 1. Schematic representation of (A) imaging and pathological traffic light classification and (B) delineate-modified Barzell zones (see Supplemental Appendix B).
Fig. 2. T2W and DWI MR images of patient 16 taken at apical and basal segments of the prostate gland and compared to schematic diagram plotting positive biopsies in the
patient’s transperineal template-guided prostate mapping biopsies, showing the cores that would be considered part of the pathological DIL.
E.J. Alexander et al. / Radiotherapy and Oncology xxx (xxxx) xxx 3are shown in Table 1. Seventeen patients (65%) had intermediate
risk and 9 (35%) high risk disease. The median interval between
diagnostic trans-rectal ultrasound-guided biopsies and study MR
was 12.2 weeks.
Median prostate volume was 39.5 cm3 (IQR 32–55 cm3) with a
median sampling density of 1.1 core/cm3 (IQR 0.9–1.3 core/cm3).
Prostate carcinoma was found in all patients. Red biopsies were
found in 24 out of 26 patients (92%); 421 DMBZ were analysed
(median 20 [IQR 11–20] per patient respectively). Traffic-light clas-
sification was; 66/421 (15.7%) of DMBZ were red and 30/421 (7.1%)
of DMBZ were amber. Twelve patients (46%) had no prostate carci-
noma sampled outside the imaged IPLs. The remainder of patients
(54%) had positive biopsies outside imaged IPLs; 1 patient had a
single amber core (3 mm Gleason 3 + 4), 13 patients had green
cores (0.5–3 mm Gleason 3 + 3). No patient had red biopsy cores
outside the imaged IPLs.
The diagnostic accuracy parameters for the T2W+DW-MR
images for readers 1 and 2 are shown in Table 2. The diagnostic
accuracy of T2W+DW-MRI was high for both readers for identifica-Please cite this article as: E. J. Alexander, J. R. Murray, V. A. Morgan et al., Valid
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org/10.1016/j.radonc.2019.07.030tion of tumour within a given sector of the prostate; sensitivity 85–
86%, specificity 93–98%, PPV 79–92% and NPV 96%. Cohen’s kappa
statistic for inter-observer agreement was 0.61 indicating good
agreement between the 2 readers. Median DIL volumes (Fig. 3A)
were 2.2 cm3 (IQR 1.4–3.1 cm3) for reader 1 and 1.54 cm3 (IQR
1.1–2.7 cm3) for reader 2. A 2nd IPL was recorded on MR in 11
patients by reader 1 (median volume 0.63 cm3 (IQR 0.34–
0.88 cm3) and in 5 patients by reader 2 (median volume 0.29 cm3
(IQR 0.27–0.38 cm3) (Fig. 3A + B).
Cancer core lengths in DILs and 2nd IPLs are shown in Fig. 3C
+ D. There was a statistically significant correlation between both
the imaged DIL volume and any imaged red lesion volume with
total cancer core length in that volume; reader 1: r = 0.44 and
0.61, p = 0.026 and 0.0001 respectively; reader 2: r = 0.50 and
0.44, p = 0.01 and 0.03 respectively (Table 3). Correlation between
the 2nd IPL volume or any imaged amber lesion volume was poorer
and did not reach statistical significance. Exploratory endpoints
including amber as well as red categories, assessment using
octants and strict rather than flexible DMBZ definitions and areation of T2- and diffusion-weighted magnetic resonance imaging for map-
-modulated radiotherapy (IMRT), Radiotherapy and Oncology, https://doi.
Table 1
Summary of patient characteristics (IQR = interquartile range).
Patient characteristics N = 26
Median age (IQR) 70.5 (66–74)
Clinical stage/radiological stage
T1c 9/0
T2 a/b 11/12
T2 c 1/9
T3a 5/5
Gleason Score at diagnosis
3 + 3 5 (19%)
3 + 4 14 (54%)
4 + 3 6 (23%)
8 1 (4%)
PSA
Median (IQR) 9.5 (5.6–17.25)
NCCN Risk Classification [1]
Intermediate 17 (65%)
High 9 (35%)
Interval between diagnostic trans-rectal
ultrasound-guided biopsies and study MR (Days)
Median (IQR) 85 (69–184)
Interval between study MR and
transperineal template-guided prostate
mapping biopsies (Days)
Median (IQR) 16.5 (11–25)
Prostate volume 39.5 (32–55)
No of cores taken 45 (38–56)
Sampling Density (cores/cc) 1.1 (0.9–1.3)
4 Validation of multiparametric MR for focal dose-escalation using IMRTshown in Supplementary Appendix C. The various methods
showed sensitivity 67–87%, specificity 84–98%, PPV 49–91% and
NPV 89–96%.Discussion
DELINEATE is the first prospective study to our knowledge
assessing the diagnostic accuracy of MR for the purposes of defin-
ing the position of a radiation boost in a population planned for
radical treatment with radiotherapy rather than prostatectomy.
TTMPB at 5 mm intervals were used as the reference standard to
achieve whole gland pathological sampling.
This study has shown that T2W+DW-MRI has good diagnostic
accuracy for mapping the location and extent of tumour lesions
measuring 0.5 cm3 or 1 cm diameter with restricted diffusion
on MR. Sensitivity, specificity and NPV was consistently high by
2 independent observers for the primary outcome measure; red
only, flexible method (85–86%, 93–98% and 96% respectively),
although the PPV varied more significantly (79–92%) due to the
low prevalence of total sectors affected by tumour. The inclusion
of amber lesions in the analysis caused a small decrease in sensitiv-
ity (78–80%) and NPV (92%). This was due to a marginal decrease inTable 2
Diagnostic accuracy parameters for T2W+DWI for both readers for Delineate modified Ba
Predictive value, NPV = Negative Predictive Value, AUC = Area under the ROC curve).
Pathological Threshold Prevalence % Sensitivity % (95
DMBZ flexible red only imaging path
threshold red
Reader 1 23 85
(77–91)
Reader 2 22 86
(78–92)
DMBZ flexible red and amber imaging
path threshold red and amber
Reader 1 30 80 (72–86)
Reader 2 28 78 (69–84)
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negatives.
Other small, single institution series have referenced MR with
WM-RP but vary in technical parameters used and so are not
strictly comparable [17,31–34]. Reported sensitivities and speci-
ficities vary widely from 23 to 96% [35–37] mainly reflecting the
prevalence of the disease, the reason for performing the test, the
variability in the threshold level for defining positive disease and
the sector level selected for analysis, all of which critically influ-
ence the reported results.
Two complementary studies have recently reported assess-
ments of MR in the diagnostic pathway for prostate cancer. The
UK PROMIS paired-cohort multicentre trial [38] investigated
mpMRI (T2W, DWI and dynamic contrast-enhanced (DCE) MR) to
define primary Gleason 4 or cancer of any grade 6 mm
(0.5 cm3) on TTMPB, demonstrating a sensitivity, specificity, PPV
and NPV of 93%, 41%, 51% and 89% respectively. However, as the
primary end-point was cancer diagnosis, the threshold chosen for
a positive MR was lower and considered the whole prostate as a
single entity. When the PROMIS data is assessed with only lesions
likely to represent cancer (exclusion of equivocal lesions), sensitiv-
ity, specificity, PPV and NPV are 70%, 78%, 70% and 84% respec-
tively, which remain lower than but more comparable with our
work. This may be explained by the different population of patients
examined, improved imaging resolution using an endorectal coil
and the multicentre nature of the PROMIS data. A similar prospec-
tive multicentre Australian study of 344 men assessed T2W/DWI/
DCE using the PI-RADS scale [19] in 344 men with a cut-off of
equivocal for positive MR. [39]. Significant prostate cancer was
defined as Gleason 7 with more than 5% grade 4, 20% of cores
positive or 7 mm of prostate cancer in any core on transperineal
template-guided prostate biopsies (median 30 cores per patient).
Sensitivity, specificity, PPV and NPV of 96%, 36%, 52% and 92% were
reported respectively which are very similar to PROMIS. Anatomi-
cal concordance of the location of imaged lesion and significant
cancer on biopsy was found in 97%. The lack of 5 mm mapping is
likely to have impacted on the ability to detect all clinically signif-
icant cancer as the size of tumour left undetected is directly related
to the uniform spacing between core samples [21]. The consistent
results of the PROMIS and Australian multicentre studies results
suggest that our findings will be generalisable.
For initial MR screening it is desirable to keep the false negative
rate as low as possible. For focal dose-escalation, where the
remainder of the prostate is getting standard doses of radiation,
it is preferable to keep the false positive rates as low as possible,
i.e., a higher specificity. Dose-escalation to false positives could
cause increased toxicity without additional benefit, thereby reduc-
ing any improvement in therapeutic ratio. In our data only 2
patients (8%) had a false positive MR when assessing the whole
prostate; one had multiple adjacent amber cores (multiple cores
of 2–5.5 mm Gleason grade 4 + 3). The second had multiple adja-
cent cores with <4 mm of tumour in the basal sections of the cores,rzell zones (DMBZ) flexible method for both pathological thresholds (PPV = Positive
%CI) Specificity % (95%CI) PPV % (95%CI) NPV % (95%CI) AUC
93
(90–96)
79
(70–86)
96
(93–97)
0.87
(0.83–0.92)
98
(96–99)
92
(84–96)
96
(93–98)
0.94
(0.91–0.98)
94 (91–96) 86 (78–91) 92 (88–94) 0.88
(0.84–0.93)
98 (95–99) 93 (86–97) 92 (88–94) 0.92
(0.89–0.95)
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Fig. 3. Measured volumes for Reader 1 (Blue) and Reader 2 (Red) of (A) dominant intraprostatic lesion, (B) second largest intraprostatic lesion, (C) cancer core length for DIL
and (D) cancer core length for 2nd IPL. Note differing scales for each figure.
Table 3
Spearman correlation coefficients for Total Cancer Core Lengths and MR defined lesions by readers 1 and 2.
Spearman correlation (q) between MR volume and pathological criteria (P value)
Total cancer core
length in DIL
Total cancer core
length in 2nd IPL
Total cancer core length
in imaged-defined red lesions
Total cancer core length
in image-defined amber lesions
Reader 1 0.44 (p = 0.026) 0.66 9 (p = 0.03) 0.61 (p < 0.0001) 0.73 (p = 0.88)
Reader 2 0.5 (p < 0.01) 0.57 (p = 0.18) 0.44 (p = 0.03) 0.32 (p = 0.478)
E.J. Alexander et al. / Radiotherapy and Oncology xxx (xxxx) xxx 5classified as green, suggesting inadequate sampling of the imaged
basal tumour.
Inter-observer agreement between the readers and correlation
between the delineated MR volumes (for the DIL and red lesions)
and the total cancer core length was good, largely a consequence
of the size of the DIL and the higher Gleason grade of these
tumours causing substantial diffusion-restriction on the DW-MRI.
Correspondingly, smaller lesions of lower Gleason grade were
more difficult to define and led to poor agreement between radiol-
ogists and poorer correlation with total cancer core length. The
inclusion of these lesions for dose boosting is questionable both
because of the imaging uncertainty and lack of need to boost smal-
ler cancer foci. Reassuringly, inter-observer agreement in the
multi-centre PROMIS trial (0.63 Cohen’s Kappa) was similar to that
in our study. In future, a combination of T2W and diffusion-
weighted imaging will generate contrast for more accurate and
even semi-automated GTV delineation.
There are several limitations to our study. First, the number of
patients was small. Second, despite the extensive sampling some
areas of prostate are difficult to fully biopsy without undue risks
to patients. These areas include the extreme base of the gland
(bladder neck injury), the supra-urethral area (urethral injury)
and pubic arch interference limiting access to the most anterior
part of larger prostate glands. In our patients this caused ‘‘false
positives” to be scored on a minority of imaging sectors. Third,Please cite this article as: E. J. Alexander, J. R. Murray, V. A. Morgan et al., Valid
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sampling the periphery rather than the centre of smaller lesions.
Although this risk is reduced with 5 mm mapping, it will have
had an effect on the analysis of total cancer core length as a surro-
gate for pathological volume. Fourth, we acknowledge the statisti-
cal analysis assesses all DMBZ and octants as independent of each
other within each patient. This is however a well-documented
approach to sector-based diagnostic accuracy studies [29,40–42].
Finally, we acknowledge that there is inevitably some uncertainty
related to the mapping of the prostate images to the stylised Bar-
zell diagram which certainly will have introduced minor geograph-
ical discrepancies between the reporting radiologists and the
pathological assessments.
We have shown that T2W+DW-MRI robustly identifies DIL for
focal boost radiotherapy, the accuracy of which underpins clinical
evaluation of such approaches. The DELINEATE trial has now
recruited over 200 patients using conventional or modest
hypofractionation schedules. A recent systematic review identified
988 patients treated with a DIL radiation boost within Phase1/2
studies which appear to be associated with low toxicity [43] even
with prolonged follow-up of 8 years [44]. DIL boosts are being
assessed in ongoing clinical phase 3 trials such as FLAME
(NCT01168479) [45,46] and PIVOTALboost (ISRCTN80146950).
In summary, focal dose escalation to DIL may be limited to
lesions 1 cm in diameter (0.5 cm3), where T2W+DW-MRI imag-
ation of T2- and diffusion-weighted magnetic resonance imaging for map-
-modulated radiotherapy (IMRT), Radiotherapy and Oncology, https://doi.
6 Validation of multiparametric MR for focal dose-escalation using IMRTing suggest a high suspicion of tumour which can be defined with
confidence. Lesions <0.5 cm3 or larger lesions less restricted on
DW-MRI should be treated with standard radiation doses. Includ-
ing these lesions in the threshold for focal boosts increases false
positives and risks increasing toxicity without therapeutic benefit.
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